- $1.22bn
- $1.17bn
- $30.91m
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Verastem rises on promising cancer drug data; Bailey succeeds Paterson as CEO
Brief: Verastem's Daniel Paterson To Retire As President And CEO, Will Remain As Advisor And Board Member
Brief: Verastem To Open TARGET-D 301 1L mPDAC Trial By Year-End 2026
Brief: Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Verastem, Tesla, Forgent
Verastem gains on positive ovarian cancer drug results
Brief: Verastem Oncology Announces New Ramp 201 Molecular Profiling And External Control Arm Analyses Describing Outcomes For Avutometinib Plus Defactinib In Recurrent Low-Grade Serous Ovarian Cancer To Be Presented At Igcs 2026
Brief: Verastem - Enters Amendment No. 3 To Note Purchase Agreement On August 6, 2026 - SEC Filing
Verastem Inc reports results for the quarter ended June 30 - Earnings Summary
Verastem Q2 revenue jumps on new product sales and milestone
Brief: Verastem Q2 Operating Expenses USD 72.788 Million
Brief: Verastem Oncology Doses First Patient In Target-D 203 Phase 2 Registration-Directed Trial Of Versus-7375 Oral Kras G12d (On/Off) Inhibitor For Kras G12d-Mutated Metastatic Colorectal Cancer
Brief: Verastem Oncology Doses First Patient In Target-D 202 Phase 2 Registration-Directed Trial Of Versus-7375 For Kras G12d-Mutated Advanced Non-Small Cell Lung Cancer
Brief: Versus-7375 Demonstrates Clinical Activity With A Favorable Safety And Tolerability Profile In Target-D 101
U.S. STOCKS ON THE MOVE-Jabil, BWX Technologies, Micron